bladder cancer

Study weighs impact of BCG shortage on outcomesUrology Times SUO internship program member William Parker, MD, discusses a retrospective review of more than 100 patients at Columbia University Medical Center in New York.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH TxOther pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCaOther pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Work-related bladder cancer risk on the riseWork-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).
The promise of PD-1 ligand pathway in treating bladder cancerResearchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.
Reprogramming cancer with a codeResearchers at Mayo Clinic’s Jacksonville, Fla., campus reported a discovery that could be the code for reprogramming cancer cells back to normal.
Product Preview: Agreement reached for phase III clinical trial of bladder Ca agentIn this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
Study: No significant link between diabetes Tx, bladder Ca
Study: No significant link between diabetes Tx, bladder CaA new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.
Best of AUA 2015: PCa surveillance, surgical controversies create buzzUrology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.